HKPD
Cellyan Biotechnology·NASDAQ
--
--(--)
--
--(--)
9.76 / 10
Outperform
Cellyan Biotechnology's fundamental score is 9.8/10, reflecting superior quality. Key metrics include Total Profit YoY growth at -97.63% (Group 3), Net Cash Flow from Operating Activities YoY growth at 244.35% (Group 1), and Diluted EPS YoY growth at -101.67% (Group 3). These suggest profitability challenges but strong operating cash flow, supporting an overall positive fundamental stance with room for improvement in earnings consistency.
Analysis Checks(2/4)
Net cash flow from operating activities per share (YoY growth rate %)
Value-30.96
Score1/3
Weight56.56%
1M Return0.65%
Value-30.96
Score1/3
Weight56.56%
1M Return0.65%
Net cash flow from operating activities (YoY growth rate %)
Value244.35
Score0/3
Weight-251.84%
1M Return-3.53%
Value244.35
Score0/3
Weight-251.84%
1M Return-3.53%
Total profit (YoY growth rate %)
Value-97.63
Score2/3
Weight165.53%
1M Return1.81%
Value-97.63
Score2/3
Weight165.53%
1M Return1.81%
Diluted earnings per share (YoY growth rate %)
Value-101.67
Score2/3
Weight129.75%
1M Return1.49%
Value-101.67
Score2/3
Weight129.75%
1M Return1.49%
Net cash flow from operating activities per share (YoY growth rate %)
Value-30.96
Score1/3
Weight56.56%
1M Return0.65%
Value-30.96
Score1/3
Weight56.56%
1M Return0.65%
Total profit (YoY growth rate %)
Value-97.63
Score2/3
Weight165.53%
1M Return1.81%
Value-97.63
Score2/3
Weight165.53%
1M Return1.81%
Net cash flow from operating activities (YoY growth rate %)
Value244.35
Score0/3
Weight-251.84%
1M Return-3.53%
Value244.35
Score0/3
Weight-251.84%
1M Return-3.53%
Diluted earnings per share (YoY growth rate %)
Value-101.67
Score2/3
Weight129.75%
1M Return1.49%
Value-101.67
Score2/3
Weight129.75%
1M Return1.49%
Is HKPD undervalued or overvalued?
- HKPD scores 9.76/10 on fundamentals and holds a Discounted valuation at present. Backed by its -0.59% ROE, -0.13% net margin, -336.23 P/E ratio, 1.82 P/B ratio, and -101.67% earnings growth, these metrics solidify its Outperform investment rating.
